Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8GFJP)

Drug Name

GX-C4 Drug Info

Synonyms

CTLA-4/Fc region of a hybrid IgG4/IgD antibody (fusion protein, autoimmune disease), Genexine

Indication

Disease Entry	ICD 11	Status	REF
Autoimmune diabetes	5A10	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cytotoxic T-lymphocyte protein 4 (CTLA-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ipilimumab	DMJTIYK	Melanoma	2C30	Approved	[2]
Tremelimumab	DMOQ9H1	Hepatocellular carcinoma	2C12.02	Approved	[1]
KN046	DMSDBPG	Non-small-cell lung cancer	2C25.Y	Phase 3	[3]
AK04	DMU7K86	Actinic keratosis	EK90.0	Phase 3	[4]
AK104	DMXJ8Z4	Cervical cancer	2C77.0	Phase 2	[5]
Lorigerlimab	DM2E8Z5	Prostate cancer	2C82.0	Phase 2	[6]
Vudalimab	DMSEEI0	Prostate cancer	2C82.0	Phase 2	[7]
AGEN1884	DMAP5B4	Cervical cancer	2C77.0	Phase 1/2	[8]
BMS-986288	DMM10J4	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[9]
MK-1308	DM25QKC	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytotoxic T-lymphocyte protein 4 (CTLA-4)	TTI2S1D	CTLA4_HUMAN	Not Available	[1]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).
2	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
3	Clinical pipeline report, company report or official report of Alphamab Oncology.
4	A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Lung Cancer. 2023 Oct;184:107355.
5	Clinical pipeline report, company report or official report of Akeso Biopharma.
6	Clinical pipeline report, company report or official report of MacroGenics
7	Clinical pipeline report, company report or official report of Xencor
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	Clinical pipeline report, company report or official report of CytomX Therapeutics.
10	Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021 Mar;32(3):395-403.